Categories
Chemistry COVID pandemic Politics Science

CDC admits that the RT-PCR test cannot distinguish between SARS-CoV-2 virus and influenza viruses

Go to the CDC website https://www.cdc.gov/csels/dls/locs/2021/07-21-2021-lab-alert-Changes_CDC_RT-PCR_SARS-CoV-2_Testing_1.html

There you read the following:

Audience: Individuals Performing COVID-19 Testing

Level: Laboratory Alert

After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.

Visit the FDA website for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, visit this page.

In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.

Categories
COVID New World Order pandemic Science vaccines

CDC to Withdraw Emergency Use Authorization for RT PCR Test Because It Cannot Distinguish Between SARS-CoV-2 and the Flu

Article reposted from Health Impact News

by Brian Shilhavy, July 25, 2021
Editor, Health Impact News

The CDC quietly announced last week that it was withdrawing its request to the FDA for Emergency Use Authorization (EUA) of the 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2.

Most of the public is probably unaware that similar to the current COVID-19 injections that are not yet approved by the FDA, but only given Emergency Use Authorization, so too the hundreds of diagnostic tests that supposedly detect COVID-19 are also NOT approved by the FDA, but only authorized via an EUA.

What is the reason the CDC is withdrawing its EUA request for the Real-Time RT-PCR Diagnostic Panel?

In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test.

CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. (Source.)

Categories
Chemistry COVID pandemic Science

No Proof of SARS-CoV-2 virus or that PCR test is accurate

The folks at Reignite Democracy Australia asked the Australian government Health department two questions under the Freedom of Information Act.

They asked for documents that provide factual scientific evidence for the existence of the China coronavirus (COVID19 SARS-CoV-2) from it being isolated from a symptomatic patient.

They asked for documents that provide factual scientific evidence beyond any reasonable doubt that the PCR test used in Australia 100% positively identifies the China coronavirus (COVID19 SARS-CoV-2) and not any other coronavirus.

They got their response. No such documents exist!